drugset / Trial / NCT01701193

A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions

NCT01701193

Phase 1/2 Completed 47 enrolled Temple Therapeutics BV
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study evaluates whether L-Alanyl-L-Glutamine can reduce the incidence, extent and severity of adhesions after myomectomy. Half of the participants will receive L-Alanyl-L-Glutamine and the other half of participants will receive a saline placebo at the time of myomectomy.

Timeline

Start
2015-02-15
Primary completion
2016-10-20
Completion
2016-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Alanyl-glutamine Peptide 1 g/kg Other

Indications